Sugi Predict

Sugi Predict / Compounds / SCHEMBL5803516

SCHEMBL5803516

SCHEMBL5803516

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CNC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 17/20 0.78
▸ LCK P06239 4/20 0.78
▸ LYN P07948 2/20 0.78
▸ NUDT14 O95848 2/20 0.73
▸ NUDT5 Q9UKK9 2/20 0.73
▸ SRC P12931 4/20 0.68
▸ KDR P35968 3/20 0.68
▸ TEK Q02763 1/20 0.68
▸ EGFR P00533 5/20 0.64
▸ ABL1 P00519 3/20 0.61
▸ HCK P08631 3/20 0.61
▸ ITK Q08881 2/20 0.61
▸ ERBB2 P04626 1/20 0.61
▸ FYN P06241 1/20 0.61
▸ YES1 P07947 1/20 0.61
▸ FGR P09769 1/20 0.61
▸ FER P16591 1/20 0.61
▸ CSK P41240 1/20 0.61
▸ TEC P42680 1/20 0.61
▸ BLK P51451 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29665749 1.00 BTK (0.78) BTKLCKLYNNUDT14NUDT5
SCHEMBL30954855 0.92 BTK (0.73) BTKLCKLYNNUDT14NUDT5
SCHEMBL14576054 0.92 BTK (0.76) BTKLCKLYNNUDT14NUDT5
SCHEMBL18335266 0.92 BTK (0.73) BTKLCKLYNNUDT14NUDT5
SCHEMBL5803386 0.92 BTK (0.76) BTKLCKLYNNUDT14NUDT5
SCHEMBL30954852 0.92 BTK (0.73) BTKLCKLYNNUDT14NUDT5
SCHEMBL29439227 0.91 BTK (0.76) BTKLCKLYNNUDT14NUDT5
SCHEMBL22720683 0.91 BTK (0.76) BTKLCKLYNNUDT14NUDT5
SCHEMBL22720762 0.90 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL26105120 0.90 BTK (0.81) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 — — US disclosed
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2024-01-18 — — US disclosed
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2024-01-18 — — US disclosed
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO, INC. (CA) 2024-01-18 — — US disclosed
EP-4247794-A2 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 Ontario, Inc. (CA) 2023-09-27 — — EP disclosed
EP-4180432-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-05-17 — — EP disclosed
US-20230055961-A1 PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF DUNAD THERAPEUTICS LTD. (GB) 2023-02-23 — — US disclosed
US-20230055961-A1 PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF DUNAD THERAPEUTICS LTD. (GB) 2023-02-23 — — US disclosed
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 ONTARIO INC (CA) 2022-09-08 — — US disclosed
EP-4017843-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF 2692372 Ontario, Inc. (CA) 2022-06-29 — — EP disclosed
EP-1212327-B8 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2004-02-25 — — EP disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1355901-A2 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a) Bristol-Myers Squibb Pharma Company (US) 2003-10-29 — — EP disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed
WO-2002055516-A2 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a) BRISTOL MYERS SQUIBB CO (US) 2002-07-18 — — WO disclosed
EP-1212327-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2002-06-12 — — EP disclosed
WO-2001019829-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof NR2E1, NR2C2, NR3C1 BTK 1670/4885LCK 2961/4885LYN 1648/4885
US-20230055961-A1 PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF FURIN, PFAS, CFTR BTK 305/4885LCK 134/4885LYN 442/4885
US-20220281812-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF BCR, ARSA, VHL BTK 226/4885LCK 1909/4885LYN 1228/4885
US-20240018153-A1 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF ABCG2, ABCB1, ARSA BTK 55/4885LCK 1211/4885LYN 659/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 BTK 1020/4885LCK 1011/4885LYN 1034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.